Stoke Therapeutics Inc
NASDAQ:STOK
Income Statement
Earnings Waterfall
Stoke Therapeutics Inc
Revenue
|
7.8m
USD
|
Operating Expenses
|
-126.3m
USD
|
Operating Income
|
-118.4m
USD
|
Other Expenses
|
9.9m
USD
|
Net Income
|
-108.5m
USD
|
Income Statement
Stoke Therapeutics Inc
Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | |||||||||||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
3
N/A
|
6
+108%
|
9
+47%
|
12
+36%
|
15
+17%
|
9
-39%
|
9
+5%
|
9
-5%
|
8
-11%
|
|
Operating Income | |||||||||||||||||||||||
Operating Expenses |
(13)
|
(17)
|
(23)
|
(29)
|
(36)
|
(41)
|
(46)
|
(50)
|
(53)
|
(58)
|
(67)
|
(76)
|
(86)
|
(97)
|
(103)
|
(111)
|
(117)
|
(119)
|
(121)
|
(122)
|
(124)
|
(126)
|
|
Selling, General & Administrative |
(4)
|
(6)
|
(7)
|
(9)
|
(12)
|
(14)
|
(17)
|
(19)
|
(21)
|
(23)
|
(26)
|
(29)
|
(32)
|
(34)
|
(37)
|
(38)
|
(39)
|
(40)
|
(40)
|
(40)
|
(41)
|
(41)
|
|
Research & Development |
(8)
|
(11)
|
(15)
|
(20)
|
(24)
|
(27)
|
(29)
|
(30)
|
(32)
|
(35)
|
(41)
|
(47)
|
(54)
|
(63)
|
(67)
|
(73)
|
(78)
|
(79)
|
(81)
|
(82)
|
(82)
|
(85)
|
|
Operating Income |
(13)
N/A
|
(17)
-35%
|
(23)
-32%
|
(29)
-29%
|
(36)
-22%
|
(41)
-15%
|
(46)
-11%
|
(50)
-8%
|
(53)
-7%
|
(58)
-10%
|
(67)
-16%
|
(76)
-13%
|
(86)
-13%
|
(94)
-9%
|
(97)
-3%
|
(102)
-5%
|
(104)
-3%
|
(104)
+0%
|
(112)
-8%
|
(112)
0%
|
(115)
-2%
|
(118)
-3%
|
|
Pre-Tax Income | |||||||||||||||||||||||
Interest Income Expense |
0
|
1
|
1
|
3
|
3
|
3
|
3
|
2
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
3
|
5
|
7
|
9
|
10
|
10
|
|
Total Other Income |
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
|
Pre-Tax Income |
(13)
N/A
|
(16)
-31%
|
(21)
-29%
|
(26)
-25%
|
(32)
-22%
|
(38)
-16%
|
(43)
-14%
|
(48)
-12%
|
(52)
-9%
|
(58)
-11%
|
(67)
-16%
|
(76)
-13%
|
(86)
-13%
|
(94)
-9%
|
(96)
-3%
|
(100)
-4%
|
(101)
-1%
|
(99)
+2%
|
(105)
-6%
|
(103)
+1%
|
(105)
-1%
|
(109)
-4%
|
|
Net Income | |||||||||||||||||||||||
Income from Continuing Operations |
(13)
|
(16)
|
(21)
|
(26)
|
(32)
|
(38)
|
(43)
|
(48)
|
(52)
|
(58)
|
(67)
|
(76)
|
(86)
|
(94)
|
(96)
|
(100)
|
(101)
|
(99)
|
(105)
|
(103)
|
(105)
|
(109)
|
|
Net Income (Common) |
(13)
N/A
|
(16)
-31%
|
(21)
-29%
|
(26)
-25%
|
(32)
-22%
|
(38)
-16%
|
(43)
-14%
|
(48)
-12%
|
(52)
-9%
|
(58)
-11%
|
(67)
-16%
|
(76)
-13%
|
(86)
-13%
|
(94)
-9%
|
(96)
-3%
|
(100)
-4%
|
(101)
-1%
|
(99)
+2%
|
(105)
-6%
|
(103)
+1%
|
(105)
-1%
|
(109)
-4%
|
|
EPS (Diluted) |
-0.41
N/A
|
-0.54
-32%
|
-0.7
-30%
|
-0.8
-14%
|
-1.07
-34%
|
-1.14
-7%
|
-1.29
-13%
|
-1.43
-11%
|
-1.56
-9%
|
-1.58
-1%
|
-1.82
-15%
|
-2.08
-14%
|
-2.34
-13%
|
-2.5
-7%
|
-2.45
+2%
|
-2.53
-3%
|
-2.6
-3%
|
-2.32
+11%
|
-2.37
-2%
|
-2.33
+2%
|
-2.38
-2%
|
-2.34
+2%
|